PARP11 interfer(on)es with CAR T cell efficacy
Author(s)
Munoz, I; Beavis, PA;
Details
Publication Year 2022-07,Volume 3,Issue #7,Page 790-792
Journal Title
Nature Cancer
Publication Type
Commentary
Abstract
Despite the remarkable success of chimeric antigen receptor (CAR) T cell therapies in the treatment of hematological malignancies, this strategy remains challenging in solid tumors. One major obstacle is the hostile immunosuppressive tumor microenvironment. New research demonstrates that targeting PARP11 can overcome this immunosuppression and boost CAR T cell efcacy through stabilization of IFNAR1.
Keywords
*T-Lymphocytes
Department(s)
Laboratory Research
PubMed ID
35883000
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-02-07 05:05:37
Last Modified: 2025-02-07 05:08:50

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙